Ayala Pharmaceuticals (NASDAQ:ADXS) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research report sent to investors on Monday morning. The firm issued a sell rating on the stock.

Ayala Pharmaceuticals Price Performance

Shares of ADXS opened at $0.02 on Monday. The company has a market capitalization of $852,600.00, a PE ratio of 0.00 and a beta of 1.55. Ayala Pharmaceuticals has a one year low of $0.00 and a one year high of $1.49. The company’s fifty day moving average price is $0.21 and its 200 day moving average price is $0.49.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.